查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
全球肾上腺素自动注射器市场-2022-2029
市场调查报告书
商品编码
1140753

全球肾上腺素自动注射器市场-2022-2029

Global Epinephrine Autoinjector Market - 2022-2029
出版日期: | 出版商: DataM Intelligence | 英文 170 Pages | 商品交期: 约2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

简介目录

市场动态

不断上升的过敏反应病例和对自我给药药物的需求不断增长正在推动市场增长。

过敏反应是对毒物、食物或药物的严重过敏反应。大多数是由蜜蜂叮咬或食用已知会引起过敏的食物引起的，例如花生和坚果。过敏反应的常见原因包括药物、花生、坚果、昆虫叮咬、鱼、贝类和牛奶。其他可能的原因包括运动和乳胶。如果怀疑有过敏反应，应尽快将肾上腺素溶液肌肉注射到大腿外侧中部，这与美国背阔肌的位置相对应。根据美国国家医学图书馆的数据，估计有 1.6% 到 5.1% 的美国公民经历过过敏反应。 PubMed 等临床数据库记录了过敏反应发病率的上升趋势。因此，预计过敏反应发病率的增加将推动肾上腺素的高使用率，这是一种急救选择，推动全球市场。吸毒器的易用性和处置性也为自动注射器创造了销售机会。这正在推动市场的增长。

但是，注射剂的多种替代方案和持续发展预计会阻碍市场增长。

地理渗透

北美将是预测期内的主要地区。

到 2021 年，北美将占据全球肾上腺素自动注射器市场的最大市场份额。该地区已经推出了几种肾上腺素自动注射器。也有通用产品。每个都含有药物肾上腺素。但是每个设备都有自己的使用说明。了解差异对于获得您想要的设备并知道如何正确使用它至关重要。患有严重过敏症的儿童可以在当地使用新的通用版本的 EpiPen 和 EpiPen Jr. 肾上腺素自动注射器。 2022 年 8 月，赛诺菲宣布 FDA 批准首款语音引导肾上腺素自动注射器用于危及生命的过敏患者，称为 Auvi-Q。该公司已从 Intelliject 获得 Auvi-Q 在北美的商业权利，而 Intelliject 保留在其他地区的商业权利。

竞争格局

全球肾上腺素自动注射器市场的主要参与者包括 ALK-Abello A/S、Amneal Pharmaceuticals Inc、Adamis Pharmaceuticals Corporation、Kaleo Inc、Mylan N.V、Novartis International AG、Pfizer Inc、Teva Pharmaceutical Industries Ltd.等。市场参与者正在努力开发具有成本效益和强大的解决方案，以获取市场份额。主要参与者采取了多种增长战略，例如产品发布、收购和合作伙伴关係，为全球肾上腺素自动注射器市场的增长做出了贡献。 2022年2月，赛诺菲完成了对Amunix的收购。此次收购提供了对 Amunix 的 Pro-XTEN、XPAT 和 XPAC 技术的访问权，以提供下一代条件激活的生物製剂。此次收购还增加了一条有前景的 T 细胞参与剂和细胞因子疗法管道。 2022 年 1 月，Amneal 收购了 Saol Therapeutics 的 Baclofen 特许经营权，这是一家私营专业製药公司。此次收购扩大了 Amneal 的神经病学商业机构和专业组合，同时在其进入生物仿製药机构市场之前增加了商业基础设施。

COVID-19 的影响。它对全球肾上腺素自动注射器市场产生了负面影响。

COVID-19 通过直接影响生产和需求、扰乱供应链、扰乱市场以及对企业和金融市场产生财务影响来影响全球经济。大多数国家/地区都放宽了封锁限制，但由于担心传播冠状病毒（COVID-19），人们不愿亲自去看医生。因此，肾上腺素自动注射器市场的公司正在拥抱远程医疗，因为在 COVID-19 时代，个人更喜欢远程医疗服务。在预测期内，对远程医疗技术的需求将急剧上升。

全球肾上腺素自动注射器市场报告提供了大约 64 个市场数据表、53 个图表和 170 页的结构。

内容

第 1 章研究方法与范围

  • 调查方法
  • 调查目的和范围

第 2 章市场定义和概述

第 3 章执行摘要

  • 按剂量划分的市场细分
  • 按年龄组划分的市场细分
  • 最终用户的市场细分
  • 按地区划分的市场细分

第 4 章市场动态

  • 市场影响因素
    • 促进因素
      • 对患者便利性的需求不断增加
    • 抑制因素
      • 偏好替代给药方式
    • 市场机会
    • 影响分析

第 5 章行业分析

  • 波特五力分析
  • 供应链分析
  • 定价分析
  • 监管分析
  • 保险报销分析
  • 未满足的需求分析

第 6 章 COVID-19 分析

  • COVID-19 的市场分析
    • COVID-19 之前的市场情景
    • COVID-19 的当前市场情景
    • COVID-19 后或未来情景
  • COVID-19 期间的价格动态
  • 供需范围
  • 大流行期间与市场相关的政府举措
  • 製造商的战略举措
  • 总结

第 7 章按剂量分类

  • 0.15mg肾上腺素自动注射器
  • 0.3mg肾上腺素自动注射器
  • 0.5mg肾上腺素自动注射器

第 8 章年龄组

  • 6 岁以下
  • 6 至 12 岁
  • 12 岁以上

第 9 章最终用户

  • 医院
  • 诊所
  • 个人

第 10 章按地区划分

  • 北美
    • 美国
    • 加拿大
    • 墨西哥
  • 欧洲
    • 德国
    • 英国
    • 法国
    • 意大利
    • 西班牙
    • 其他欧洲
  • 南美洲
    • 巴西
    • 阿根廷
    • 其他南美洲
  • 亚太地区
    • 中国
    • 印度
    • 日本
    • 澳大利亚
    • 其他亚太地区
  • 中东和非洲

第 11 章竞争格局

  • 竞争场景
  • 市场情况/份额分析
  • 併购分析

第 12 章公司简介

  • Mylan Inc.
    • 公司概况
    • 产品组合和描述
    • 主要亮点
    • 财务摘要
  • ALK-Abello AS
  • Adamis Pharmaceuticals Corp.
  • Amneal Pharmaceuticals Inc.
  • Teva Pharmaceutical Industries Ltd.
  • Amedra Pharmaceuticals LLC
  • Sanofi Sa
  • Lincoln Medical Ltd
  • Antares Pharma Inc.
  • Novartis AG
  • Pfizer Inc.（Hospira Inc.）（List Not Exhaustive）

第 13 章 DataM

简介目录
Product Code: DMPH2877

Market Overview

Epinephrine Autoinjector Market was valued at USD XX million in 2021. It is forecasted to reach USD XX million by 2029, growing at a CAGR of XX % during the forecast period (2022-2029).

Epinephrine (adrenaline) is a medicine used to treat conditions such as asthma, cardiac arrest, superficial bleeding, and anaphylaxis. It can also be used by inhalation for croup. Epinephrine autoinjectors are hand-held devices carried by those with severe allergies; the epinephrine delivered by the device is an emergency treatment for an anaphylactic reaction. Epinephrine autoinjector is also called EpiPen; a device used to inject a measured dose of adrenaline by autoinjector technology. The device is capable of intramuscular injection for instant and better results. The pen is designed specifically to avoid accidental punctures in the skin, as the syringe is enclosed under a protected shield and needs to operate manually to inject when kept on the patient's skin. The global Epinephrine Autoinjector Market growth is driven by several factors, such growing prevalence of allergies and their awareness among customers, increasing advancement in the product with cost-effective solutions, and rising demand for autoinjectors instead of traditional syringes.

Market Dynamics: Growing cases of anaphylaxis and rising demand for self-administered drugs are driving the market growth.

Anaphylaxis is a severe allergic reaction to the venom, food, or medication. Mostly it is caused by a bee sting or eating foods that are known to cause allergies, such as peanuts or tree nuts. Common causes of anaphylaxis include medication, peanuts, tree nuts, insect stings, fish, shellfish, and milk. Other causes may include exercise and latex. When anaphylaxis is suspected, epinephrine solution is given as soon as possible as an intramuscular injection in the middle of the outer side of the thigh, which corresponds to the location of the vast us lateral muscle. According to the national library of medicine, between 1.6% and 5.1% of US citizens are estimated to have experienced anaphylaxis. Clinical databases such as PubMed have captured the growing prevalence of anaphylaxis. Therefore, the growing incidence of anaphylaxis is likely to increase the high uptake of epinephrine as it is the first-aid treatment option, thereby driving the global market. Ease of usage and disposal of drug injectors has created opportunities for autoinjectors. This, in turn, is boosting the market's growth.

However, multiple alternatives for injections and continuous advancements are expected to hamper the market growth.

Market Segmentation: The 0.3mg epinephrine auto-injector segment is projected to be the dominant segment in the market during the forecast period.

Based on dosage, the market is segmented into 0.15mg epinephrine auto-injector, 0.3mg epinephrine auto-injector, and 0.5mg epinephrine auto-injector.

The 0.3mg epinephrine auto-injector accounted for the largest market share due to its various applications across all age groups and moderate doses, among others. The growth of this segment is expected to have an exponential rise during the forecast period. The National Institute of Allergy and Infectious Diseases guidelines recommend epinephrine as a first-line treatment option. The prevalence of food allergies is high in children. Various studies have shown the majority of food allergy incidences, including anaphylaxis, occur in schools or daycare centres. Hence, epinephrine auto-injectors are considered an integral part of emergency care in schools and daycare centres.

The rising incidence of anaphylaxis in the adults & elderly is a primary factor driving the growth of the 0.5mg epinephrine auto-injector dose segment. Epinephrine is considered the first-line treatment for anaphylaxis. In addition, market players are focusing on providing generic, low-cost products. This is raising the demand for affordable treatment options for managing anaphylactic reactions.

Based on Age Group, the age group 6-12 years segment is expected to held significant market share in the fastest CAGR over the forecast period.

The age group 6-12 years children are more prone to anaphylaxis and are currently experiencing the leading position in the market and are expected to grow significantly in the forecast period. However, the prevalence of anaphylaxis is increasing in the geriatric population and is expected to grow at a considerable pace. The burden of anaphylaxis among children is growing, which requires quick and effective management. The government and regulatory bodies are giving safeguards to prevent fatal reactions among children in the 6-12 years of age group. The epinephrine, through auto-injectors, acts fast and can rapidly treat the most dangerous symptoms in children. Thus, it has always been recommended to make ready epinephrine auto-injectors for children in schools to avoid fatal conditions. Therefore, this is driving the segment growth.

Geographical Penetration: North America is the dominating region during the forecast period.

North America accounted for the largest market share of the global epinephrine autoinjector market in 2021. Several epinephrine autoinjectors are now available in the region. There are generic versions as well. Each contains the drug epinephrine. But, each device possesses its own unique set of instructions for use. Understanding the differences are essential to get the device one wants and knowing how to use it properly. Children with severe allergies now have access to a new generic version of EpiPen and EpiPen Jr. Epinephrine autoinjectors in the region. In August 2022, Sanofi Announces FDA Approval for its first voice-guided Epinephrine Auto-injector for Patients with Life-threatening Allergies named, Auvi-Q. The company has licensed the North American commercialization rights to Auvi-Q from Intelliject, Inc., which has retained commercialization rights for the rest of the world.

Competitive Landscape:

Some of the major players in the global epinephrine autoinjector market include ALK-Abello A/S, Amneal Pharmaceuticals Inc, Adamis Pharmaceuticals Corporation, Kaleo Inc, Mylan N.V, Novartis International AG, Pfizer Inc, Teva Pharmaceutical Industries Ltd., among others. The market players are involved in developing cost-effective and robust solutions to gain market share. The major players are adopting several growth strategies, such as product launches, acquisitions, and collaborations, which are contributing to the growth of the Epinephrine Autoinjector Market globally. In February 2022, Sanofi completed the acquisition of Amunix. This acquisition provides access to Amunix Pro-XTEN, XPAT, and XPAC technology to deliver next-generation Conditionally Activated Biologics. Also, this acquisition adds a promising pipeline of T-cell engagers and cytokine therapies. In January 2022, Amneal acquired Saol Therapeutics' Baclofen Franchise, a private specialty pharmaceutical company. The acquisition expands Amneal's commercial institutional and specialty portfolio in neurology while adding commercial infrastructure in advance of its entry into the biosimilar institutional market.

COVID-19 Impact: Negative impact on the global epinephrine autoinjector market.

COVID-19 affects the global economy by directly affecting production and demand, disturbing the supply chain and market disruption, and having a financial impact on firms and financial markets. Most countries have relaxed lockdown regulations, but people are reluctant to visit doctors in person due to the fear of spreading coronavirus (COVID-19). Thus, companies in the epinephrine autoinjector market are adopting telemedicine as individuals prefer remote healthcare services during the COVID-19 era. The demand for telehealth technology will rise dramatically during the forecast period.

The global epinephrine autoinjector market report would provide an access to approximately 64 market data tables, 53 figures and 170 pages

Table of Contents

1. Methodology and Scope

  • 1.1. Research Methodology
  • 1.2. Research Objective and Scope of the Report

2. Market Definition and Overview

3. Executive Summary

  • 3.1. Market Snippet by Dosage
  • 3.2. Market Snippet by Age Group
  • 3.3. Market Snippet by End-User
  • 3.4. Market Snippet by Region

4. Market Dynamics

  • 4.1. Market Impacting Factors
    • 4.1.1. Drivers
      • 4.1.1.1. Increasing Demand for Convenience of Patients
      • 4.1.1.2. XX
    • 4.1.2. Restraints
      • 4.1.2.1. Preference for Alternative Drug Delivery Modes
      • 4.1.2.2. XX
    • 4.1.3. Opportunity
    • 4.1.4. Impact Analysis

5. Industry Analysis

  • 5.1. Porter's Five Forces Analysis
  • 5.2. Supply Chain Analysis
  • 5.3. Pricing Analysis
  • 5.4. Regulatory Analysis
  • 5.5. Reimbursement Analysis
  • 5.6. Unmet Needs

6. COVID-19 Analysis

  • 6.1. Analysis of Covid-19 on the Market
    • 6.1.1. Before COVID-19 Market Scenario
    • 6.1.2. Present COVID-19 Market Scenario
    • 6.1.3. After COVID-19 or Future Scenario
  • 6.2. Pricing Dynamics Amid Covid-19
  • 6.3. Demand-Supply Spectrum
  • 6.4. Government Initiatives Related to the Market During Pandemic
  • 6.5. Manufacturers Strategic Initiatives
  • 6.6. Conclusion

7. By Dosage

  • 7.1. Introduction
  • 7.2. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Dosage Segment
  • 7.3. Market Attractiveness Index, By Dosage Segment
    • 7.3.1. 0.15mg Epinephrine Autoinjector*
      • 7.3.1.1. Introduction
      • 7.3.1.2. Market Size Analysis, and Y-o-Y Growth Analysis (%)
    • 7.3.2. 0.3mg Epinephrine Autoinjector
    • 7.3.3. 0.5mg Epinephrine Autoinjector

8. By Age Group

  • 8.1. Introduction
  • 8.2. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Age Group Segment
  • 8.3. Market Attractiveness Index, By Age Group Segment
    • 8.3.1. Under 6 Years Patients*
      • 8.3.1.1. Introduction
      • 8.3.1.2. Market Size Analysis, and Y-o-Y Growth Analysis (%)
    • 8.3.2. 6 to 12 Years Patients
    • 8.3.3. Over 12 Years Patients

9. By End-User

  • 9.1. Introduction
  • 9.2. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End-User
  • 9.3. Market Attractiveness Index, By End-User Segment
    • 9.3.1. Hospitals*
      • 9.3.1.1. Introduction
      • 9.3.1.2. Market Size Analysis, and Y-o-Y Growth Analysis (%)
    • 9.3.2. Clinics
    • 9.3.3. Individuals

10. By Region

  • 10.1. Introduction
  • 10.2. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Region
  • 10.3. Market Attractiveness Index, By Region
  • 10.4. North America
    • 10.4.1. Introduction
    • 10.4.2. Key Region-Specific Dynamics
    • 10.4.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Dosage
    • 10.4.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Age-Group
    • 10.4.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End-User
    • 10.4.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 10.4.6.1. U.S.
      • 10.4.6.2. Canada
      • 10.4.6.3. Mexico
  • 10.5. Europe
    • 10.5.1. Introduction
    • 10.5.2. Key Region-Specific Dynamics
    • 10.5.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Dosage
    • 10.5.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Age-Group
    • 10.5.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End-User
    • 10.5.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 10.5.6.1. Germany
      • 10.5.6.2. U.K.
      • 10.5.6.3. France
      • 10.5.6.4. Italy
      • 10.5.6.5. Spain
      • 10.5.6.6. Rest of Europe
  • 10.6. South America
    • 10.6.1. Introduction
    • 10.6.2. Key Region-Specific Dynamics
    • 10.6.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Dosage
    • 10.6.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Age-Group
    • 10.6.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End-User
    • 10.6.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 10.6.6.1. Brazil
      • 10.6.6.2. Argentina
      • 10.6.6.3. Rest of South America
  • 10.7. Asia Pacific
    • 10.7.1. Introduction
    • 10.7.2. Key Region-Specific Dynamics
    • 10.7.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Dosage
    • 10.7.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Age-Group
    • 10.7.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End-User
    • 10.7.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 10.7.6.1. China
      • 10.7.6.2. India
      • 10.7.6.3. Japan
      • 10.7.6.4. Australia
      • 10.7.6.5. Rest of Asia Pacific
  • 10.8. Middle East and Africa
    • 10.8.1. Introduction
    • 10.8.2. Key Region-Specific Dynamics
    • 10.8.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Dosage
    • 10.8.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End-User

11. Competitive Landscape

  • 11.1. Competitive Scenario
  • 11.2. Market Positioning/Share Analysis
  • 11.3. Mergers and Acquisitions Analysis

12. Company Profiles

  • 12.1. Mylan Inc.*
    • 12.1.1. Company Overview
    • 12.1.2. Product Portfolio and Description
    • 12.1.3. Key Highlights
    • 12.1.4. Financial Overview
  • 12.2. ALK-Abello AS
  • 12.3. Adamis Pharmaceuticals Corp.
  • 12.4. Amneal Pharmaceuticals Inc.
  • 12.5. Teva Pharmaceutical Industries Ltd.
  • 12.6. Amedra Pharmaceuticals LLC
  • 12.7. Sanofi Sa
  • 12.8. Lincoln Medical Ltd
  • 12.9. Antares Pharma Inc.
  • 12.10. Novartis AG
  • 12.11. Pfizer Inc.( Hospira Inc.) (List Not Exhaustive)

13. DataM Intelligence

  • 13.1. Appendix
  • 13.2. About Us and Services
  • 13.3. Contact Us